US FDA Approves Palsonify, First Once-Daily Oral Pill for Rare Hormonal Disorder Acromegaly

Spread the Message

Read Time:4 Minute, 35 Second

The U.S. Food and Drug Administration (FDA) has approved Palsonify (paltusotine), developed by Crinetics Pharmaceuticals, as the first once-daily oral therapy for adults with acromegaly, a rare hormonal disorder caused by excessive growth hormone production from the pituitary gland. The approval, announced on September 25, 2025, marks a significant advancement in managing this challenging condition, offering patients an easier alternative to injectable treatments that have long been the standard of care.

Acromegaly affects an estimated 3 to 14 people per 100,000 worldwide, characterized by abnormal enlargement of bones and tissues leading to profound changes in facial features, hands, and feet, as well as complications like diabetes, hypertension, and cardiovascular disease. Typically resulting from a benign pituitary tumor, unchecked growth hormone secretion increases levels of insulin-like growth factor 1 (IGF-1), the primary biomarker for disease monitoring.

Key Clinical Findings
The FDA’s decision was supported by results from two pivotal Phase 3 clinical trials, PATHFNDR-1 and PATHFNDR-2, encompassing both patients previously treated with surgery or injectable therapies and those who were treatment-naive. These trials demonstrated that Palsonify rapidly and reliably controlled IGF-1 levels and reduced symptom burden. Notably, patients reported improvements across a spectrum of acromegaly symptoms, including headaches, joint pain, excessive sweating, fatigue, and swelling, measured using the FDA-aligned Acromegaly Symptom Diary tool.

Longer-term data from open-label extension phases showed sustained biochemical control and an encouraging safety profile, with most participants continuing treatment without serious adverse events. The oral pill’s mechanism targets the somatostatin receptor type 2 (SST2), a critical mediator in inhibiting growth hormone release, making it a nonpeptide SST2 agonist with a novel pharmacologic profile.

Expert Perspectives
Dr. Shlomo Melmed, Executive Vice President of Medicine and Health Sciences at Cedars-Sinai, remarked, “The approval of Palsonify is a significant advancement for our patients… addressing a critical unmet need for a convenient, safe therapy with rapid and durable efficacy.” He emphasized that the once-daily oral administration could improve adherence and quality of life compared with existing injectable options that require regular administration and are associated with breakthrough symptoms.

Jill Sisco, President of the Acromegaly Community, highlighted the impact on patients: “What matters most to our community – maintaining consistent control so the disease doesn’t control us – led us to partner with the FDA on patient-focused drug development. This new treatment reflects that our voices have been heard,” reinforcing the value of patient involvement in shaping therapeutic advances.

Context and Background
Historically, treatment options for acromegaly included surgery, radiation therapy, and long-acting injectable somatostatin analogs or growth hormone receptor antagonists, all of which can be burdensome and inconvenient. Injectable drugs often require visits to healthcare providers or self-injections, impacting adherence and lifestyle. The availability of Palsonify as an oral pill streamlines therapy and may reduce patient burden significantly.

Palsonify’s approval also represents a first commercial product for Crinetics Pharmaceuticals, a company focused on endocrine disorders. The company is also pursuing regulatory submissions for Palsonify in the European Union and developing it for carcinoid syndrome, another rare neuroendocrine condition.

Public Health Implications
While acromegaly is a rare disease, the burden on those affected is substantial, ranging from physical disfigurement to systemic metabolic complications. Effective management that ensures biochemical control can prevent or mitigate these consequences. Palsonify’s oral formulation may improve treatment uptake and consistency, potentially reducing disease-associated morbidity and healthcare costs related to complications.

However, the treatment’s annual cost, reported at approximately $290,000, poses challenges for accessibility and affordability. Crinetics has launched a patient support program, CrinetiCARE, to assist with education, insurance benefits, and financial resources to help patients navigate treatment barriers.

Limitations and Considerations
Although clinical trials showed Palsonify to be generally well tolerated, the drug’s long-term real-world safety will need continued monitoring post-approval. Moreover, the clinical trial populations were relatively small due to the rarity of acromegaly, which may limit the generalizability of findings across diverse patient subsets.

Furthermore, Palsonify will compete with established injectable therapies already proven effective. Whether patient preference for oral administration translates into superior long-term outcomes remains to be seen, emphasizing the need for individualized treatment decisions under medical guidance.

Practical Takeaways for Readers
For individuals living with acromegaly or caring for someone with the condition, Palsonify represents an innovative treatment option that may simplify ongoing disease management. However, treatment decisions should always be made in close consultation with endocrinologists and healthcare professionals experienced in this rare disorder.

Continuing to monitor symptoms and biochemical markers like IGF-1 is essential regardless of the therapy used. Patients are encouraged to discuss with their physicians if this new oral treatment might be appropriate for their specific clinical situation.

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References